Wu-heng YUE, Rui MEI, Juan CAI, et al. Preparation of Juglone-loaded PLGA Nanoparticles and Its Anti-tumor Effect on Melanoma A375 Cells in Vitro[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(4): 87-93.
DOI:
Wu-heng YUE, Rui MEI, Juan CAI, et al. Preparation of Juglone-loaded PLGA Nanoparticles and Its Anti-tumor Effect on Melanoma A375 Cells in Vitro[J]. Chinese journal of experimental traditional medical formulae, 2019, 25(4): 87-93. DOI: 10.13422/j.cnki.syfjx.20190114.
Preparation of Juglone-loaded PLGA Nanoparticles and Its Anti-tumor Effect on Melanoma A375 Cells in Vitro
To prepare Juglone-loaded poly lactic-co-glycolic acid nanoparticles (Jug-PLGA-NPs)
and investigate their physicochemical properties
release characteristics
in vitro
and anti-tumor activities on A375 melanoma cells
in vitro
.
Method:
2
Jug-PLGA-NPs were prepared by emulsification-solvent evaporation method. Then the particle size
encapsulation efficiency
drug loading rate and
in vitro
release characteristics were investigated. Fluorescence microscopy was used to observe the uptake of PLGA-NPs
in vitro
. The distribution of PLGA-NPs in BALB/c nude mice after tail vein injection was observed by the small living animal imaging system. Their inhibition effect on proliferation of A375 cells was detected by thiazolyl blue tetrazolium bromide (MTT) assay. Apoptosis rate and cell cycle detection were performed by flow cytometry. Western blot was used to determine the protein kinase B (Akt)
phosphorylated Akt (p-Akt) and cyclinD
1
.
Result:
2
The average particle size of the prepared Jug-PLGA-NPs was (149.6±21.5) nm
entrapment rate of (68.39±2.51)%
and drug-loading rate of (5.07±0.98)%
showing good sustained-release characteristics. PLGA-NPs showed good penetration and targeting properties in cellular uptake
in vitro
and
in vivo
imaging. Different concentrations of Jug-PLGA-NPs could significantly inhibit the proliferation and promote apoptosis of A375 cells in a time and concentration dependent manner (
P
<
0.05)
and its 48 h effect was superior to that of the same concentration of Jug. The mechanism may be related to the regulation of Akt phosphorylation level
down-regulation of cyclinD
1
expression (
P
<
0.05) and the cell-cycle arrest in G
0
/G
1
phase (
P
<
0.05).
Conclusion:
2
The Jug-PLGA-NPs are easy to prepare and have good sustained-release characteristics
tumor targeting and anti-tumor ability
providing a new pharmaceutical dosage form for the future clinical application of Jug.
关键词
Keywords
references
Siegel R L , Miller K D , Ahmedin-Jemal D P. Cancer statistics, 2018 [J]. CA Cancer J Clin , 2018 , 68 ( 1 ): 7 - 30 .
BAO L , Kimzey A , Sauter G , et al . Prevalent overexpression of prolyl isomerase Pin1 in human cancers [J]. Am J Pathol , 2004 , 164 ( 5 ): 1727 - 1737 .
MIN S H , ZHOU X Z , LU K P. The role of Pin1 in the development and treatment of cancer [J]. Arch Pharm Res , 2016 , 39 ( 12 ): 1609 - 1620 .
Hennig L , Christner C , Kipping M , et al . Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone [J]. Biochemistry , 1998 , 37 ( 17 ): 5953 - 5960 .
FANG F , QIN Y X , QI L , et al . Juglone exerts antitumor effect in ovarian cancer cells [J]. Iran J Basic Med Sci , 2015 , 18 ( 6 ): 544 - 548 .
JI Y B , XIN G S , QU Z Y , et al . Mechanism of juglone-induced apoptosis of MCF-7 cells by the mitochondrial pathway [J]. Genet Mol Res , 2016 , 15 ( 3 ): 123 - 131 .
Aithal B K , Kumar M R , RAO B N , et al . Juglone, a naphthoquinone from walnut, exerts cytotoxic and genotoxic effects against cultured melanoma tumor cells [J]. Cell Biol Int , 2009 , 33 ( 10 ): 1039 - 1049 .
JIN J , ZHANG Y , LI Y , et al . RNA-interference-mediated downregulation of Pin1 suppresses tumorigenicity of malignant melanoma A375 cells [J]. Neoplasma , 2012 , 60 ( 1 ): 92 - 100 .
Arasoglu T , Derman S , Mansuroglu B , et al . Synthesis, characterization and antibacterial activity of juglone encapsulated PLGA nanoparticles [J]. J Appl Microbiol , 2017 , 123 ( 6 ): 1407 - 1419 .
ZHANG Z , QIAN H , YANG M , et al . Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment [J]. Int J Nanomedicine , 2017 , 12 : 1593 - 1605 .
GUO J , SI L , KONG Y , et al . Phase Ⅱ, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification [J]. J Clin Oncol , 2011 , 29 ( 21 ): 2904 - 2909 .
Kruiswijk F , Hasenfuss S C , Sivapatham R , et al . Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling [J]. Oncogene , 2016 , 35 ( 17 ): 2166 - 2177 .
Kim G , Kim J Y , Lim S C , et al . SUV39H1/DNMT3A-dependent methylation of the RB1 promoter stimulates PIN1 expression and melanoma development [J]. Faseb J , 2018 , doi: fj201700645 doi:fj201700645 .
XU G G , Etzkorn F A. Pin1 as an anticancer drug target [J]. Drug News Perspect , 2009 , 22 ( 7 ): 399 - 407 .
Hariharan N , Sussman M A. Pin1: a molecular orchestrator in the heart [J]. Trends Cardiovasc Med , 2014 , 24 ( 6 ): 256 - 262 .
Bartek J , Lukas J. DNA repair: Cyclin D 1 multitasks [J]. Nature , 2011 , 474 ( 7350 ): 171 - 172 .
Liou Y C , Ryo A , HUANG H K , et al . Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes [J]. Proc Natl Acad Sci U S A , 2002 , 99 ( 3 ): 1335 - 1340 .
TAO X , ZHANG H , Park S S , et al . Loss of Pin1, suppresses hedgehog-driven medulloblastoma tumori-genesis 1 [J]. Neoplasia , 2017 , 19 ( 3 ): 216 - 225 .
CHAO S H , Greenleaf A L , Price D H. Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription [J]. Nucleic Acids Res , 2001 , 29 ( 3 ): 767 - 773 .